ArticleJournal of neurology2025
Clinical course and long-term outcomes in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- CD11c + microglia: From basic research to clinical application.Neural regeneration research · 2026Article
- Early Clinical and Cerebrospinal Fluid Predictors of 1-Year Recurrence in Autoimmune GFAP Astrocytopathy.Annals of clinical and translational neurology · 2026Article
- Characteristics and prognostic factors of cognitive impairment in autoimmune glial fibrillary acidic protein astrocytopathy.Journal of neurology · 2026Article
- Efgartigimod as adjunctive therapy in refractory autoimmune glial fibrillary acidic protein astrocytopathy: a case series.Journal of neurology · 2026Article
- Clinical characteristics of late-onset adult autoimmune glial fibrillary acidic protein astrocytopathy: a retrospective cohort study.Journal of neurology · 2026Article
- Prominent urinary dysfunction and delayed antibody detection in patients with glial fibrillary acidic protein astrocytopathy: a case series analysis.BMC neurology · 2026Article
- Investigation of Prognostic Factors in Patients With Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.European journal of neurology · 2026Article
- Age at onset distinguishes clinical features and relapse risk in autoimmune glial fibrillary acidic protein astrocytopathy.Frontiers in immunology · 2026Article
- Article
- The Associations of Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammatory Index with the Severity and Prognosis of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.Journal of inflammation research · 2025Article
- Transient Visual Obscurations and Systemic Symptoms Unveiling Glial Fibrillary Acidic Protein Astrocytopathy.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe aim was to describe the clinical course and long-term outcomes of the French cohort of patients with glial fibrillary acidic protein (GFAP) astrocytopathy.
methodsPatients with positive CSF GFAP antibody test were identified between May 2017 and February 2023. Those whose clinical presentation occurred < 2 years before the initiation of the study, with other diagnosis than GFAP astrocytopathy, and with missing clinical information were excluded.
resultsAmong the 74 patients included, 71 were alive at last follow-up. The median age at onset was 43 years (range 6-84), 44 patients were male (62%), and 11 (15%) had a neoplasia. The main initial syndrome was meningo-encephalitis (n = 41, 58%). The median follow-up was 28 months (range 1-129). The median mRS at presentation was 4 (range 1-5) and at last follow-up was 1 (range 0-4). Forty patients reported disability at last follow-up (56%). The most frequent sequelae were cognitive complaints (20/40, 50%) and gait disorder (19/40, 48%). 38/55 patients (69%) returned to school/work. Long-term immunoactive treatment was introduced in 40 patients (56%); the most commonly administered were oral corticosteroids (n = 35, 49%). Relapses were documented in 10 patients (14%) and occurred after a median follow-up of 9 months (range 3-46). The presence of concomitant tumor at onset was associated with relapse (HR 4.55, 95% CI 1.28-16.14, p = 0.03).
conclusionsThis study suggests a greater impact than previously described in long-term outcomes of patients with GFAP astrocytopathy and reports concomitant tumor at presentation as a risk factor for relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.